

## ACUTE MYOCARDIAL INFARCTION CLINICAL DATA REGISTRY: AN EFFORT TO PROMOTE CLINICAL FEEDBACK AND QUALITY IMPROVEMENT FOR ACUTE MYOCARDIAL INFARCTION

Sohail Aziz, Naseer Ahmed Samore, Rehana Khadim, Imran Fazal, Tariq Hussain Khattak, Farhan Tayyab,  
Aysha Siddiq

Armed Forces Institute of Cardiology/National Institute of Heart Diseases Rawalpindi, Pakistan

### ABSTRACT

**Objective:** To evaluate the clinical characteristics and in hospital outcomes of the patients with acute myocardial infarction in tertiary care cardiac hospital.

**Study Design:** Descriptive cross-sectional study.

**Place and Duration of Study:** Adult Cardiology Department of Armed Forces Institute of Cardiology & National Institute of Heart Diseases, from 1<sup>st</sup> January 2015 till 31<sup>st</sup> August, 2015.

**Material and Methods:** All the patients presenting with acute myocardial infarction during the study period were included. Acute myocardial infarction registry by R & D Department was used as a data collection tool.

**Results:** Total 829 patients presented with acute myocardial infarction during our study duration. Males were 704(84.9%) while females were 125 (15.1%). Mean age of the patients was found to be  $61.56 \pm 2.19$  years. Acute myocardial infarction was most prevalent in the age group 58-75 years. The most common symptom with which patients presented was angina 682 (82.1%). Patients with ST segment elevated MI (STEMI) were 702 (84.6%) while anterior wall myocardial infarction was the most common STEMI site 456 (64.8%). Injection Streptokinase was given to 255 (30.7%) patients with mean door to needle time  $20 \pm 2.1$  minutes. Primary percutaneous intervention (PCI) was performed to the 447 (55%) of the patients, with mean door to balloon time  $55 \pm 1.5$  minutes.

**Conclusion:** Acute myocardial infarction (MI) remains a leading cause of morbidity and mortality. Early management of MI can increase the life expectancy and quality of life of the patients.

**Keywords:** Myocardial infarction, Primary percutaneous intervention, ST segment elevated MI.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### INTRODUCTION

Ischemic heart disease is the number one cause of death in the Western world as well as developing world and constitutes an immense public health problem<sup>1,2</sup>. The burden of ischemic heart disease is increasing in parallel with the increase in life expectancy<sup>3,4</sup>. As more persons live with heart diseases, the burden of prevalent diseases with its associated co-morbid complications is increasing. Identifying persons with heart diseases, measuring the incidence of disease and its outcome becomes essential as multifaceted approaches to reduce the burden of disease. In this context, myocardial infarction occupies a central role in the assessment of the burden of heart diseases<sup>4,5</sup>. Acute myocardial infarction (MI) remains a leading cause of

morbidity and mortality worldwide<sup>3</sup>. Myocardial infarction occurs when diminished blood supply to the heart, exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal operating function and homeostasis<sup>4</sup>. Ischemia at this critical threshold level for an extended period results in irreversible myocardial cell damage or death<sup>2,5</sup>.

Approximately 1.5 million cases of myocardial infarction occur annually in the United States<sup>5</sup>. Myocardial infarction is a key component of the burden of cardiovascular diseases<sup>4</sup>. The assessment of the incidence and case fatality of myocardial infarction are important determinants of the decline in coronary disease mortality<sup>6</sup>.

### MATERIAL AND METHODS

Data was collected through myocardial

**Correspondence:** Dr Naseer Samore, Cardiologist AFIC, Rawalpindi, Pakistan (Email: [naseer\\_samore@gmail.com](mailto:naseer_samore@gmail.com))

infarction clinical registry by Research & Development Department of AFIC & NIHD. Data was collected from 1st January till 31st August, 2015. All the patients presenting with acute myocardial infarction during the study

duration were included in the study.

Clinical registry was used to collect the data of the patients with acute myocardial infarction. Registry was specifically designed to measure the demographics of the patients, clinical signs and symptoms, risk factors, lab

**Table: Demographics, clinical presentations, procedure details and post-procedure complications of patients presented with myocardial infarction.**

S. No	Variables	Frequency (n)	Percentage(%)
<b>Demographics</b>			
1	Gender: <ul style="list-style-type: none"> <li>• Male</li> <li>• Female</li> </ul>	704 125	84.9% 15.1%
2	Ethnicity: <ul style="list-style-type: none"> <li>• Punjabi</li> <li>• Others</li> <li>• Pashtun</li> <li>• Kashmiri</li> <li>• Sindhi</li> </ul>	703 47 41 37 1	84.6% 5.6% 4.9% 4.5% 0.1%
3	Age (Mean±SD)	61.56 ± 2.19 years	
4	Age Groups: <ul style="list-style-type: none"> <li>• &lt;20 years</li> <li>• 21-38 years</li> <li>• 39-57 years</li> <li>• 58-75 years</li> <li>• ≥ 75 years</li> </ul>	0 14 148 600 67	0% 1.7% 17.8% 72.4% 8.1%
<b>Clinical Presentations</b>			
5	Risk Factors: <ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Diabetes Millitus</li> <li>• Smoking</li> <li>• Family History</li> </ul>	185 125 80 75	22.3% 15.1% 9.6% 9.0%
6	Symptoms: <ul style="list-style-type: none"> <li>• Angina</li> <li>• Shortness of Breath</li> <li>• Syncope</li> </ul>	682 116 152	82.1% 14.0% 18.4%
7	Heart Failure Classes: <ul style="list-style-type: none"> <li>• KILLIP Class I</li> <li>• KILLIP Class II</li> <li>• KILLIP Class III</li> <li>• KILLIP IV</li> </ul>	689 60 51 28	83.2% 7.2% 6.2% 3.4%
8	Lab Investigations: <ul style="list-style-type: none"> <li>• ECG Changes</li> <li>• Elevated Cardiac Biomarkers (CK &amp; CKMB)</li> <li>• Deranged Lipid Profile</li> <li>• Deranged Renal Functional Tests</li> <li>• Impaired Glucose Levels</li> </ul>	802 497 157 118 127 100	96.7% 60.0% 18.9% 14.3% 15.4% 12.0%
9	Type of Myocardial Infarction: <ul style="list-style-type: none"> <li>• STEMI (ST-Segment Elevated MI)</li> <li>• NSTEMI (Non-ST Segment Elevated MI)</li> </ul>	702 127	84.6% 15.3%
10	Sites of STEMI: <ul style="list-style-type: none"> <li>• Anterior</li> <li>• Inferior</li> <li>• Lateral</li> <li>• Posterior</li> </ul>	456 203 26 17	64.8% 29.0% 3.7% 2.5%
<b>Procedure Details</b>			
11	Streptokinase Given	255	30.7%
12	Primary PCI	447	55.0%
13	Door to Needle time for Streptokinase (Mean ±S.D)	20 ± 2.1 minutes	
14	Door to Balloon time for Primary PCI (Mean ±S.D)	53 ± 1.5 minutes	
15	Mortality <ul style="list-style-type: none"> <li>i. Not willing for Primary PCI</li> <li>ii. Late for injection Streptokinase</li> <li>iii. STEMI                             <ul style="list-style-type: none"> <li>▪ Streptokinase Given</li> <li>▪ Primary PCI</li> </ul> </li> <li>iv. NSTEMI</li> </ul>	105 40 10 18 24 13	12.7% 4.8% 1.2% 2.1% 2.8% 1.6%
<b>Post-Procedure Complications</b>			
16	• Stent thrombosis	11	1.3%
17	• Cardiogenic Shock	9	1.1%
18	• CVA	26	5%

investigations, site and type of myocardial infarction, procedural details and post procedure complications. Formal approval was taken from Institutional Ethical review board AFIC & NIHD.

Data was analyzed using SPSS-21 version. Quantitative variables were described with their mean  $\pm$  S.D while qualitative variables were described with their frequency and valid percentages.

## RESULTS

There were total 829 patients presented with acute myocardial infarction during our study duration i.e. January 2015 till August 2015. Out of which males were more in number 704(84.9%) as compared to females 125(15.1%). Most of the patients were of Punjabi ethnicity 703(84.6%). Mean age of the patients was found to be  $61.56 \pm 2.19$  years. Acute myocardial infarction was most prevalent in the age group 58-75 years 600(72.4%), followed by 148(17.8%) in the age group 39-57 and 67(8.1%) in the age group  $\geq 75$  years. The most common symptom with which patients presented was angina 682 (82.1%) then syncope 152(18.4%) and shortness of breath 116(14%).

KILLIP Class I (no heart failure) was found in 689(83.2%) patients, KILLIP II in 60(7.2%), KILLIP III in 51(6.2%) and KILLIP IV was found in 28(3.4%) of acute myocardial infarction patients.

96% patients had ECGs changes while 497 (60%) patients had elevated cardiac enzymes (CK & CKMB). 18.9% patients had deranged lipid profile, 15.4% patients had impaired glucose levels while 4.1% patients had deranged renal functional tests. Patients with ST segment elevated MI (STEMI) were 702(84.6%) while Non-ST segment elevated MI were 127(15.3%). Anterior wall myocardial infarction was the most common STEMI site 456(64.8%).

Procedural details showed that Injection Streptokinase was given to 255(30.7%) patients with mean door to needle time  $20 \pm 2.1$  minutes. Injection streptokinase was given to those STEMI patients who were not willing for Primary PCI. Primary percutaneous coronary

intervention (PCI) was performed to the 447(55%) of the patients, with mean door to balloon time  $55 \pm 1.5$  minutes. Primary percutaneous intervention was performed to the patients who were late for injection streptokinase. Mortality in the hospital due myocardial infarction or its complications was 12.7%.

## DISCUSSION

Myocardial infarction is the leading cause of death throughout the world<sup>7</sup>. Approximately 450, 000 people in the United States die from coronary diseases per year<sup>6</sup>. The survival rate for U.S. patients hospitalized with MI is approximately 95%<sup>8</sup>.

The incidence of MI increases with age; however, the actual incidence is dependent on predisposing risk factors for atherosclerosis<sup>7</sup>. Our study has helped us in understanding various factors associated with acute myocardial infarction in our local population. The mean age in our study subjects was  $61.56 \pm 2.1$  years. This result was in accordance with the results of different studies conducted all around the world<sup>8-10</sup>. Approximately 50% of all myocardial infarctions in the United States occur in people younger than 65 years<sup>5</sup>. In our study population the most prevalent age group for MI was 58-75 years. However, in the future, as demographics shift and the mean age of the population increases, a larger percentage of patients presenting with MI would be older than 65 years<sup>7</sup>.

Cardiovascular risk factors play a pivotal role in the occurrence of myocardial infarction<sup>8</sup>. Our study results exhibited that smoking history, hypertension and diabetes were major risk factors for MI which is concordant with the previous published data from the developing countries<sup>9</sup>.

The common sites of ST-segment elevated myocardial infarction in our study were anterior wall MI 392(64.8%) and inferior wall MI 175 (29%). This is in agreement with the documented data from both the developed and third world countries<sup>10-12</sup>. Majority of the patients had KILLIP class-I of MI 689 (83.2%) followed by KILLIP class-II 60 (7.2%). This

result was especially in accordance with our neighboring countries<sup>9,13</sup>.

The interesting finding of our study was the procedural details which showed the best quality of health care and patient management at AFIC & NIHD. Injection streptokinase was given to 255 (30.7%) patients with mean door to needle time 20 ± 2.1 minutes while Primary percutaneous intervention (PCI) was performed to the 447(55%) patients of MI. Overall mortality in the hospital due to myocardial infarction or its complications was 12.7%.

**CONCLUSION**

Acute myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Early management of MI can increase the life expectancy and quality of life of the patients.

**CONFLICT OF INTEREST**

This study has no conflict of interest to declare by any author.

**REFERENCES**

1. American Medical Association. What is a Clinical Data Registry [Internet]. National Quality Registry Network ; 2014 [ cited 2016 Feb 1]. Available from:
2. <http://www.abms.org/media/1358/what-is-a-clinical-data-registry>

3. Monash University, Medicine, Nursing and Health Sciences [Internet]. Australia: Monash University; 2016 [cited on 2016 Feb 1]. Available from:
4. <http://www.med.monash.edu.au/epidemiology/units-centres/registries/>
5. Thom T, Haase N, et al. Writing Group Members. Heart Disease and Stroke Statistics--2006 Update. Circulation; A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee; January 11; 2006. CIRCULATIONAHA.105.171600.
6. Feinleib M, Lentzner H, Collins J, Pokras R, Havlik R. Regional variations in coronary heart disease mortality and morbidity. In: Luepker Ha., editor. Trends in coronary heart disease mortality. Oxford University Press; 2010.
7. NHLBI Morbidity and Mortality Chart Book. Bethesda, Md: National Heart, Lung, and Blood Institute; 2004.
8. CARDIOL JAC.INCIDENT AND PREVALENCE OF ACUTE MYOCARDIAL INFARCTION IN CANADA. JACC Journal. March 2015. Volume 65 (Issue 10) doi:10.1016/S0735-1097(15)61385-7.
9. Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: A review of the literature. Archives of Cardiovascular Diseases. March 2011; Volume 104 (Issue 3): Pages 178–188.
10. Hoyer A. Management of chronic total occlusion by percutaneous coronary intervention. Heart 2012, 98:822–828.
11. Illuminati G, Ricco JB, Greco C, Mangieri E, Calio F, Ceccanei G, et al. Systematic preoperative coronary angiography and stenting improves postoperative results of carotid endarterectomy in patients with asymptomatic coronary artery disease: a randomized controlled trial. Eur J VascEndovasc Surg2010;39(2):139-45.
12. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al.Heart disease and stroke statistics-2011 update: areport from American heart association. Circulation 2011;123(4):e18-e209.
13. Hussain S, Kayani AM, Munir R, Trans-radial primary percutaneous coronary intervention in ST-Elevation Myocardial Infarction. Coll Physician Surg Pak.2014 Feb;24(2)78-81.
14. Ohira T, Cardiovascular disease epidemiology in Asia: an overview. Circ J.2013;77(7)1646-52.
15. Frederick G,Hand M, Sidney C. 2009 FocusedUpdates,ACC/AHA Guidelines for the management of patients with ST Elevation Myocardial Infarction.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Paretical Guidelines. Circulation 2009;120:2271-2306

.....